Effects of Melatonin Supplementation in Type 2 Diabetes Mellitus
Keywords:
diabetes mellitus, melatonin, glucose, insulin, obesityAbstract
Background: Diabetes mellitus, a metabolic illness causing hyperglycemia, is primarily caused by insulin resistance. Melatonin, an indolamine, plays a role in the circadian cycle and affects hunger, fullness, and awareness. Melatonin treatment has shown positive effects on glycated hemoglobin, fasting plasma glucose, and insulin levels, but may increase insulin sensitivity and reduce fasting insulin levels. Methods: This systematic review focused on full-text English literature published between 2014 and 2024 using the PRISMA 2020 guidelines. Editorials and review pieces published in the same journal as the submission without a DOI were not accepted. The literature was compiled using PubMed, ScienceDirect, and SagePub, among other online venues. Result: Our study team initially collected more than 100,000 publications using reliable sources including Science Direct, PubMed, and SagePub. Just five publications were found to be directly related to our ongoing systematic examination after a rigorous three-level screening approach. Subsequently, a comprehensive analysis of the complete text was conducted, and additional scrutiny was given to these articles. To facilitate viewing, Table 1 gathers together the literature that was examined for this analysis. Conclusion: Melatonin, a hormone, can affect glycemic control, obesity control, and energy expenditure. It regulates insulin secretion and protects against reactive oxygen species and free radicals. However, high levels can negatively affect insulin sensitivity.
References
Zheng, Y., Ley, S. H., & Hu, F. B. (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology, 14(2), 88–98. https://doi.org/10.1038/nrendo.2017.151
Abdul-Ghani, M., Jayyous, A., Asaad, N., Helmy, S., & Al-Suwaidi, J. (2018). Pioglitazone and cardiovascular risk in T2DM patients: is it good for all? Annals of Translational Medicine, 6(10), 192–192. https://doi.org/10.21037/atm.2018.03.19
Hannemann, J., Laing, A., Middleton, B., Schwedhelm, E., Marx, N., Federici, M., Kastner, M., Skene, D. J., & Böger, R. (2024). Effect of oral melatonin treatment on insulin resistance and diurnal blood pressure variability in night shift workers. A double-blind, randomized, placebo-controlled study. Pharmacological Research, 199(September 2023). https://doi.org/10.1016/j.phrs.2023.107011
Lorenzo-Medina, M., De La Iglesia, S., Ruiz-Garciá, L., Quintana-Hidalgo, L., Martiń-Alfaro, R., & Herrada, J. (2013). Pitfalls of glycated hemoglobin in the glycemic assessment of diabetes patients with hemoglobin Louisville: Role of serum fructosamine. Journal of Diabetes Science and Technology, 7(3), 804–805. https://doi.org/10.1177/193229681300700329
Battelino, T., & Dovč, K. (2020). Glycemic variability: The danger of a physiologically stable metric. Journal of Clinical Endocrinology and Metabolism, 105(10), 3815–3817. https://doi.org/10.1210/clinem/dgaa486
Martorina, W., & Tavares, A. (2023). Glycemic Variability in Patients with Type 2 Diabetes Mellitus (T2DM): The Role of Melatonin in a Crossover, Double-Blind, Placebo-Controlled, Randomized Study. Nutrients, 15(16). https://doi.org/10.3390/nu15163523
Reutrakul, S., Sumritsopak, R., Saetung, S., Chanprasertyothin, S., Chailurkit, L. or, & Anothaisintawee, T. (2018). Lower nocturnal urinary 6-sulfatoxymelatonin is associated with more severe insulin resistance in patients with prediabetes. Neurobiology of Sleep and Circadian Rhythms, 4(March 2017), 10–16. https://doi.org/10.1016/j.nbscr.2017.06.001
Zhang, X., Xie, L., Zhong, M., Yang, B., Yang, Q., Yang, H., & Xie, C. (2020). The association between melatonin receptor 1B gene polymorphisms and type 2 diabetes mellitus (T2DM) in Chinese populations: A meta-analysis. Annals of Cardiothoracic Surgery, 9(3), 957–966. https://doi.org/10.21037/apm-20-691
Zhu, H., Zhao, Z. jia, Liu, H. yi, Cai, J., Lu, Q. kang, Ji, L. dan, & Xu, J. (2023). The melatonin receptor 1B gene links circadian rhythms and type 2 diabetes mellitus: an evolutionary story. Annals of Medicine, 55(1), 1262–1286. https://doi.org/10.1080/07853890.2023.2191218
Lauritzen, E. S., Kampmann, U., Pedersen, M. G. B., Christensen, L. L., Jessen, N., Møller, N., & Støy, J. (2022). Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes—A randomized placebo-controlled crossover trial. Journal of Pineal Research, 73(1). https://doi.org/10.1111/jpi.12809
Zhou, Z., Sun, B., Huang, S., Zhu, C., & Bian, M. (2020). Glycemic variability: adverse clinical outcomes and how to improve it? Cardiovascular Diabetology, 19(1), 1–14. https://doi.org/10.1186/s12933-020-01085-6
Lauritzen, E. S., Kampmann, U., Smedegaard, S. B., & Støy, J. (2021). Effects of daily administration of melatonin before bedtime on fasting insulin, glucose and insulin sensitivity in healthy adults and patients with metabolic diseases. A systematic review and meta-analysis. Clinical Endocrinology, 95(5), 691–701. https://doi.org/10.1111/cen.14576
Bazyar, H., Zare Javid, A., Bavi Behbahani, H., Moradi, F., Moradi Poode, B., & Amiri, P. (2021). Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial. Trials, 22(1), 1–10. https://doi.org/10.1186/s13063-021-05174-z
Satari, M., Bahmani, F., Reiner, Z., Soleimani, A., Aghadavod, E., Kheiripour, N., & Asemi, Z. (2021). Metabolic and anti-inflammatory response to melatonin administration in patients with diabetic nephropathy. Iranian Journal of Kidney Diseases, 15(1), 22–30.
Bazyar, H., Javid, A. Z., Zakerkish, M., Yousefimanesh, H. A., & Haghighi-Zadeh, M. H. (2022). Effects of melatonin supplementation in patients with type 2 diabetes mellitus and chronic periodontitis under nonsurgical periodontal therapy: A double-blind randomized controlled trial. Journal of Research in Medical Sciences, 27(1), 52. https://doi.org/10.4103/jrms.JRMS_927_19
Rezvanfar, M. R., Heshmati, G., Chehrei, A., Haghverdi, F., Rafiee, F., & Rezvanfar, F. (2017). Effect of bedtime melatonin consumption on diabetes control and lipid profile. International Journal of Diabetes in Developing Countries, 37(1), 74–77. https://doi.org/10.1007/s13410-016-0497-2
Hadi, A., Ghaedi, E., Moradi, S., Pourmasoumi, M., Ghavami, A., & Kafeshani, M. (2019). Effects of Melatonin Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hormone and Metabolic Research, 51(3), 157–164. https://doi.org/10.1055/a-0841-6638
Li, J., Li, N., Yan, S., Lu, Y., Miao, X., Gu, Z., & Shao, Y. (2019). Melatonin attenuates renal fibrosis in diabetic mice by activating the AMPK/PGC1α signaling pathway and rescuing mitochondrial function. Molecular Medicine Reports, 19(2), 1318–1330. https://doi.org/10.3892/mmr.2018.9708
Raygan, F., Ostadmohammadi, V., Bahmani, F., Reiter, R. J., & Asemi, Z. (2019). Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition, 38(1), 191–196. https://doi.org/10.1016/j.clnu.2017.12.004
Prado, N. J., Ferder, L., Manucha, W., & Diez, E. R. (2018). Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension. Current Hypertension Reports, 20(5). https://doi.org/10.1007/s11906-018-0842-6
Erland, L. A. E., & Saxena, P. K. (2017). Melatonin Natural Health Products and Supplements: Presence of serotonin and significant variability of melatonin content. Journal of Clinical Sleep Medicine, 13(2), 275–281. https://doi.org/10.5664/jcsm.6462
Delpino, F. M., Figueiredo, L. M., & Nunes, B. P. (2021). Effects of melatonin supplementation on diabetes: A systematic review and meta-analysis of randomized clinical trials. Clinical Nutrition, 40(7), 4595–4605. https://doi.org/10.1016/j.clnu.2021.06.007
Cipolla-Neto, J., & Do Amaral, F. G. (2018). Melatonin as a Hormone: New Physiological and Clinical Insights. In Endocrine Reviews (Vol. 39, Issue 6). https://doi.org/10.1210/er.2018-00084
Garaulet, M., Lopez-Minguez, J., Dashti, H. S., Vetter, C., Hernández-Martínez, A. M., Pérez-Ayala, M., Baraza, J. C., Wang, W., Florez, J. C., Scheer, F. A. J. L., & Saxena, R. (2022). Interplay of Dinner Timing and MTNR1B Type 2 Diabetes Risk Variant on Glucose Tolerance and Insulin Secretion: A Randomized Crossover Trial. Diabetes Care, 45(3), 512–519. https://doi.org/10.2337/dc21-1314
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Daniel Setiawan Nathan, Hoo Yumilia (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
